Publications by authors named "C Guidone"
Background: Observational studies suggest that bariatric-metabolic surgery might greatly improve non-alcoholic steatohepatitis (NASH). However, the efficacy of surgery on NASH has not yet been compared with the effects of lifestyle interventions and medical therapy in a randomised trial.
Methods: We did a multicentre, open-label, randomised trial at three major hospitals in Rome, Italy.
Introduction: Single Anastomosis Duodenal-Ileal Bypass with Sleeve Gastrectomy (SADI-S), like other hypoabsorptive procedures, could be burdened by long-term nutritional deficiencies such as malnutrition, anemia, hypocalcemia, and hyperparathyroidism.
Objectives: We aimed to report our experience in terms of mid-term (2 years) bariatric, nutritional, and metabolic results in patients who underwent SADI-S both as a primary or revisional procedure.
Methods: One hundred twenty-one patients were scheduled for SADI-S as a primary or revisional procedure from July 2016 to February 2020 and completed at least 2 years of follow-up.
Aim: To investigate the prevalence of biopsy-proven non-alcoholic steatohepatitis (NASH) in a cohort of patients with morbid obesity and with or without type 2 diabetes (T2D) and to find non-invasive predictors of NASH severity.
Methods: We evaluated a cohort of 412 subjects (age 19-67 years, body mass index-BMI: 44.98 kg/m), who underwent fine-needle liver biopsy during bariatric surgery.
Aims: Duodenal mucosal resurfacing (DMR) is an endoscopic procedure developed to improve metabolic parameters and restore insulin sensitivity in patients with diabetes. Here we report long-term DMR safety and efficacy from the REVITA-1 study.
Materials And Methods: REVITA-1 was a prospective, single-arm, open-label, multicenter study of DMR feasibility, safety, and efficacy in patients with type 2 diabetes (hemoglobin A1c [HbA1c] of 7.
Article Synopsis
- The study aimed to evaluate the effectiveness of metabolic surgery compared to medical therapy for treating type 2 diabetes over a 10-year follow-up period.
- Out of 60 patients, those undergoing biliopancreatic diversion (BPD) had the highest diabetes remission rate at 50%, while medical therapy had only 5.5% and Roux-en-Y gastric bypass (RYGB) had 25%.
- Most patients who maintained remission at 2 years experienced relapses, but all had satisfactory glycemic control by the end of the 10-year period, and surgical patients experienced fewer diabetes-related complications than those receiving medical therapy.